Sabin

Vaccine R&D Leader Kathrin Jansen and Immunologist Kizzmekia Corbett Awarded Sabin’s Gold Medal and Rising Star Respectively

Retrieved on: 
Wednesday, December 7, 2022
Fever Dream, Gold medal, Rising Star, RSV, Friends, Respiratory syncytial virus, Mumps, R, Head, Merck & Co., Coronavirus, BioNTech, Gold, Mentorship, Health, Sabin, Partnership, Inbar Lavi, FDA, DRS, Rotavirus, Pfizer, Public health, Ecosystem, HPV, Harvard T.H. Chan School of Public Health, Vaccine, Degenerative disease, Doctor of Philosophy, Sabin Vaccine Institute, Streptococcus pneumoniae, Education, STEM, RNA transfection, Infection, Pneumonia, Measles, Research, Cervical cancer, Rubella, Pandemic, Rising Star Award, COVID-19, Policy, Pharmaceutical industry

WASHINGTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today honored two extraordinary scientists for their breakthrough vaccine research that changed the course of the COVID-19 pandemic, advanced public health, and saved countless lives. The 2022 Albert B. Sabin Gold Medal was awarded to vaccine research leader Kathrin U. Jansen, PhD, and the Rising Star to immunologist Kizzmekia Corbett, PhD.

Key Points: 
  • The 2022 Albert B. Sabin Gold Medal was awarded to vaccine research leader Kathrin U. Jansen, PhD, and the Rising Star to immunologist Kizzmekia Corbett, PhD.
  • This past August, Dr. Jansen retired as the senior vice president and head of vaccine research and development at Pfizer Inc.
  • Previously, she directed vaccine R&D efforts at Merck Research Laboratories and led the development of the world’s first cervical cancer vaccine.
  • “Her contributions to vaccine development are matched only by her dedication to shoring up vaccine confidence, especially among skeptics.

Sabin Receives Additional $21.8 Million From BARDA to Advance Marburg Vaccine

Retrieved on: 
Wednesday, September 14, 2022
Disability, Safety, Development, Biomedical Advanced Research and Development Authority, Human, Department, Sabin, Policy, Twitter, Office of Inspector General, U.S. Department of Health and Human Services, Virus, United States Department of Health and Human Services, BARDA, Administration, Sabin Vaccine Institute, Partnership, U.S. Department of Defense Strategy for Operating in Cyberspace, Primate, Viral hemorrhagic fever, Human services, Vaccine, Solution, DRC, Marburg virus disease, Ecosystem, Research, GLOBE, Animal, Ebola River, Disease, Death

The Sabin Marburg vaccine is the only candidate currently slated for a Phase 2 clinical trial.

Key Points: 
  • The Sabin Marburg vaccine is the only candidate currently slated for a Phase 2 clinical trial.
  • The latest tranche of funds enables Sabin to conduct a randomized, blinded, placebo-controlled clinical trial among adults in the U.S. to further evaluate the safety and the efficacy of the Marburg vaccine candidate and advance non-clinical vaccine dosing studies.
  • In 2019, BARDA awarded Sabin a multi-year contract valued at $128 million to further the development of vaccines against two lethal viruses: Marburg and Ebola Sudan.
  • The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation.

The Rockefeller Foundation Launches the Vaccination Action Network to Strengthen Health Systems and Scale Up Covid-19 Vaccinations in sub-Saharan Africa

Retrieved on: 
Tuesday, August 2, 2022
Sabin, Rockefeller Foundation, COVID-19, Human, INGO, Twitter, Makerere University, Vaccine hesitancy, Research, Partnership, Solution, Personal protective equipment, Amref Health Africa, Amref International University, Sabin Vaccine Institute, Infectious Diseases Institute, USD, List of health departments and ministries, International, Organization, Leadership, Policy, Ministry, Technology, Ecosystem, Science, Immunization, VAN, Global Health Security Initiative, Vaccination, Program, Communication, HIV, IDI, GVI, Vaccine, Pharmaceutical industry, Medical device, Wakiso Town, Health

NAIROBI, Kenya, August 2, 2022 /PRNewswire/ -- The Rockefeller Foundation announces the launch of the Vaccination Action Network (VAN), a USD$7.4 million locally-led, peer-to-peer learning initiative designed to engage public health decision-makers across sub-Saharan Africa and bolster their efforts to strengthen health systems while scaling up Covid-19 vaccine demand strategies. Sabin Vaccine Institute and Dalberg are the secretariat for the network, while Amref Health Africa (Amref) is playing a key role to guide and administer subgrants to local organizations in participating countries so that they can implement vaccine demand generation strategies discussed during the learning sessions.

Key Points: 
  • "The Vaccination Action Network's community-based approach brings together our counterparts from across the region and country.
  • This collaboration is the key to finding and implementing the right vaccination approach," said Dr. Diana Atwine, Permanent Secretary, Ministry of Health, Uganda.
  • While more than 60 percent of people have been fully vaccinated against Covid-19 globally, just 20 percent of people in Africa have received full doses.
  • "The Vaccination Action Network is helping to establish new channels of communication that will consistently elevate regional learnings, solutions, and leadership," said William Asiko, Vice President of The Rockefeller Foundation Africa Regional Office.

Cincinnati Children’s Hospital Medical Center and Orange Grove Bio Establish Collaboration to Develop and Commercialize Novel Therapeutics

Retrieved on: 
Wednesday, March 9, 2022
University, Faculty, B cell, National, Laboratory, Orange, Cincinnati Children's Hospital Medical Center, Entrepreneurship, Drug development, Partnership, Research, Therapy, Hospital, Respiratory distress syndrome, Academic health science centre, Education, Autoimmunity, Cancer, OGB, Lists of diseases, Health, Child, Inflammation, Technology transfer, GLOBE, News, Patient, CID, Â, Disease, Sabin, Bypass (road), Cincinnati metropolitan area, Biotechnology, U.S. News & World Report, Pharmaceutical industry

CINCINNATI, March 09, 2022 (GLOBE NEWSWIRE) -- Orange Grove Bio, a preclinical drug investment and development firm, and Cincinnati Childrens Hospital Medical Center today announced the establishment of a collaboration designed to advance the development and commercialization of novel therapeutics by supporting the translation of scientific discoveries made by researchers at Cincinnati Childrens.

Key Points: 
  • CINCINNATI, March 09, 2022 (GLOBE NEWSWIRE) -- Orange Grove Bio, a preclinical drug investment and development firm, and Cincinnati Childrens Hospital Medical Center today announced the establishment of a collaboration designed to advance the development and commercialization of novel therapeutics by supporting the translation of scientific discoveries made by researchers at Cincinnati Childrens.
  • Under terms of the collaboration, Orange Grove Bio will provide commercialization guidance and support to Cincinnati Childrens Innovation Ventures.
  • Orange Grove Bio fosters strong relationships with technology transfer offices outside of the traditional medical technology hubs of Boston and San Francisco.
  • Additional information about technologies developed at Cincinnati Childrens may be found at Innovation.CincinnatiChildrens.org
    Orange Grove Bio (OGB) is an emerging, preclinical, capital allocation and asset development biotech company.

PharmaJet Vaccine Delivery Featured at Sabin Vaccine Institute Conference

Retrieved on: 
Tuesday, March 1, 2022
Science, Other Science, Biotechnology, Pharmaceutical, Medical Supplies, Health, Medical Devices, Infectious Diseases, WHO, Social media, U.S. FDA, Vaccine, Research, Policy, Immunization, World, Sabin Vaccine Institute, CE marking, Gonzaga University, Twitter, Ecosystem, LinkedIn, Aircraft, Vaccination, Vaccine hesitancy, Certification, Solution, Polio, Use, System, COVID-19, Needle, CEO, Sabin, Caregiver, Injection, Child, Technology, Review, Partnership, Poster, World Health Organization, PQS, PharmaJet, the Sabin Vaccine Institute, the Vaccine Acceptance and Demand Initiative (VARN), PHARMAJET, THE SABIN VACCINE INSTITUTE, THE VACCINE ACCEPTANCE AND DEMAND INITIATIVE (VARN)

The poster, entitled Needle-free delivery of vaccines bridges vaccine coverage gaps in Somalia and Pakistan, is authored by J.V.

Key Points: 
  • The poster, entitled Needle-free delivery of vaccines bridges vaccine coverage gaps in Somalia and Pakistan, is authored by J.V.
  • Recent WHO-sponsored introductions of needle-free intradermal delivery of inactivated polio vaccine (ID-IPV) in Pakistan and Somalia have resulted in the immunization of over 3 million children.
  • The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation.
  • The Sabin Vaccine Institutes Vaccine Acceptance and Demand program is actively building a multidisciplinary, global network referred to as the Vaccination Acceptance Research Network (VARN).

Istari Oncology Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its Viral Immunotherapy PVSRIPO

Retrieved on: 
Tuesday, October 26, 2021
Safety, Fujifilm, Head, Melanoma, Biotechnology, CDMO, Research Triangle Park, Sabin, Vaccine, Knowledge, FDB, Contract, A-DNA, Partnership, Patient, CGMP, FDA, Food, Immortalised cell line, Mitsubishi, PVSRIPO, CD155, RTP, Diosynth, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Glioblastoma, Patent, Mitsubishi Corporation, Solution, APC, GLOBE, Tumor microenvironment, Bladder cancer, Pharmaceutical industry

FUJIFILM Diosynth Biotechnologies is a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies.

Key Points: 
  • FUJIFILM Diosynth Biotechnologies is a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies.
  • Istari Oncology selected FUJIFILM Diosynth Biotechnologies as its partner for drug substance manufacturing and filling of its recombinant viral immunotherapy PVSRIPO, which is based on the Sabin Type 1 poliovirus vaccine.
  • Drug substance manufacturing and filling will be carried out in FUJIFILM Diosynth Biotechnologies state-of-the-art cGMP manufacturing facility in College Station, Texas.
  • Our decision to collaborate with FUJIFILM Diosynth Biotechnologies on the manufacturing of PVSRIPO has already paid off in multiple ways, said Jamie Iudica, chief manufacturing officer, Istari Oncology.

Sabin Vaccine Institute Receives Additional $34.5 Million from BARDA for Further Development of Ebola Sudan and Marburg Vaccines

Retrieved on: 
Thursday, October 21, 2021
Safety, Death, Research, DRC, Assistant, Vaccine Research Center, Ecosystem, Filoviridae, Vaccine, Disease, Sabin, Marburg virus disease, Military personnel, Sabin Vaccine Institute, Viral hemorrhagic fever, Public Health Emergency of International Concern, Human, BARDA, Twitter, Partnership, Virus, Ebola River, Ebola, Primate, World Health Organization, Public health emergency, World, Ministry of Health (Saudi Arabia), Policy, Office of the Assistant Secretary for Preparedness and Response, Office of Inspector General, U.S. Department of Health and Human Services, Ministry, Biomedical Advanced Research and Development Authority, Polio, Infection, Public health, COVID-19, WHO, Solution, Development, GSK, GLOBE, Animal, Pharmaceutical industry

In September 2019, BARDA awarded Sabin a development contract, valued up to $128 million, and has already provided funding of $40.5 million.

Key Points: 
  • In September 2019, BARDA awarded Sabin a development contract, valued up to $128 million, and has already provided funding of $40.5 million.
  • The two candidate vaccines, based on GSKs proprietary ChAd3 platform, were exclusively licensed to the Sabin Vaccine Institute from GSK in 2019.
  • Ebola Sudan and Marburg are members of the Filoviridae virus family and are commonly referred to as filoviruses.
  • Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and southern Sudan.

Sabin Vaccine Institute Names Richard Adegbola and Yacine Djibo to Board of Trustees

Retrieved on: 
Tuesday, May 25, 2021
Medical specialties, Vaccination, Vaccine, Virology, Sabin

WASHINGTON, May 25, 2021 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) announced that Professor Richard Adegbola and Yacine Djibo have been elected to the Board of Trustees.

Key Points: 
  • WASHINGTON, May 25, 2021 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) announced that Professor Richard Adegbola and Yacine Djibo have been elected to the Board of Trustees.
  • Professor Adegbola is a research professor at the Nigerian Institute of Medical Research and a consultant for Immunization & Global Health, RAMBICON.
  • With the appointment of Professor Adegbola and Ms. Djibo, Sabins board consists of 14 members.
  • The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation.

Vaccine Science and Policy Experts Call for Transformation of Vaccine R&D Enterprise

Retrieved on: 
Tuesday, May 4, 2021
Medical specialties, Vaccination, Sabin, Vaccine, Health care, Medicine

The meeting of the Sabin-Aspen Vaccine Science & Policy Group and its research and report were funded by the Bill & Melinda Gates Foundation and the Wellcome Trust.\nThe Sabin-Aspen Vaccine Science & Policy Group, a partnership launched in 2018 between the Sabin Vaccine Institute and the Aspen Institute , brings together senior leaders across many disciplines to examine some of the most challenging vaccine-related issues and drive impactful change.

Key Points: 
  • The meeting of the Sabin-Aspen Vaccine Science & Policy Group and its research and report were funded by the Bill & Melinda Gates Foundation and the Wellcome Trust.\nThe Sabin-Aspen Vaccine Science & Policy Group, a partnership launched in 2018 between the Sabin Vaccine Institute and the Aspen Institute , brings together senior leaders across many disciplines to examine some of the most challenging vaccine-related issues and drive impactful change.
  • Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases.
  • At Sabin, we believe in the power of vaccines to change the world.
  • Founded in 1949, the Institute drives change through dialogue, leadership and action to help solve the most important challenges facing the United States and the world.

LG Chem to Contribute to Global Polio Eradication with Eupolio™, the First Sabin Inactivated Polio Vaccine to Receive WHO Prequalification

Retrieved on: 
Thursday, January 7, 2021
Oncology, Health, Diabetes, General Health, Pharmaceutical, Biotechnology, Medical specialties, Companies, Vaccination, Polio, Economy of South Korea, Vaccines, Vaccine, Virology, Polio vaccine, LG Chem, LG Corporation, Sabin

LG Chem announced today that its Sabin-Inactivated Polio Vaccine (Sabin-IPV) Eupolio received World Health Organization (WHO) prequalification effective December 21st, 2020, enabling it to be supplied globally as early as this month.

Key Points: 
  • LG Chem announced today that its Sabin-Inactivated Polio Vaccine (Sabin-IPV) Eupolio received World Health Organization (WHO) prequalification effective December 21st, 2020, enabling it to be supplied globally as early as this month.
  • LG Chem initiated the development of Eupolio in 2014 and invested in the construction of a state of the art WHO Global Action Plan III compliant manufacturing facility in Osong, Korea.
  • LG Chem developed Korea's first recombinant hepatitis B vaccine, Euvax, and has since supplied it to more than 80 countries worldwide for the past 20 years.
  • LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally.